These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 26566289)

  • 21. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
    Schlüter B; Gerhards R; Strumberg D; Voigtmann R
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 Gene Amplification by Fluorescence In Situ Hybridization (FISH) Compared With Immunohistochemistry (IHC) in 122 Equivocal Gastric Cancer Cases.
    Liu X; Wang X; Wang B; Ren G; Ding W
    Appl Immunohistochem Mol Morphol; 2016 Aug; 24(7):459-64. PubMed ID: 26317310
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma.
    Nergiz D; Alikanoğlu AS; Süren D; Gömceli İ; Öztürk B
    Indian J Pathol Microbiol; 2022; 65(2):321-327. PubMed ID: 35435366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 status in lung adenocarcinoma: a comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations.
    Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Uehara T; Fujimoto M; Tsuruyama T; Date H; Haga H
    Lung Cancer; 2014 Sep; 85(3):373-8. PubMed ID: 25047676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human epidermal growth factor receptor 2 amplification detection by droplet digital polymerase chain reaction in formalin-fixed paraffin-embedded breast and gastric cancer samples.
    Wang X; Wu Y; Song X; Sun C; Wu C; Feng H
    J Cancer Res Ther; 2017; 13(4):730-734. PubMed ID: 28901323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.
    Agersborg S; Mixon C; Nguyen T; Aithal S; Sudarsanam S; Blocker F; Weiss L; Gasparini R; Jiang S; Chen W; Hess G; Albitar M
    Breast Cancer Res Treat; 2018 Jul; 170(2):321-328. PubMed ID: 29564742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma.
    Huber AR; Buscaglia B; Koltz BR; Henry J; McMahon L; Guo J; Hicks DG; Whitney-Miller CL
    Am J Clin Pathol; 2019 Apr; 151(5):461-468. PubMed ID: 30624589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability of immunocytochemistry and fluorescence in situ hybridization on fine-needle aspiration cytology samples of breast cancers: A comparative study.
    Acs B; Szekely N; Szasz AM; Lotz G; Szekely T; Istok R; Szekely E; Madaras L; Kulka J; Jaray B
    Diagn Cytopathol; 2016 Jun; 44(6):466-71. PubMed ID: 26990933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.
    Anglesio MS; Kommoss S; Tolcher MC; Clarke B; Galletta L; Porter H; Damaraju S; Fereday S; Winterhoff BJ; Kalloger SE; Senz J; Yang W; Steed H; Allo G; Ferguson S; Shaw P; Teoman A; Garcia JJ; Schoolmeester JK; Bakkum-Gamez J; Tinker AV; Bowtell DD; Huntsman DG; Gilks CB; McAlpine JN
    J Pathol; 2013 Jan; 229(1):111-20. PubMed ID: 22899400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
    Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
    Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
    Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
    Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concordance of HER2 Immunohistochemistry and Fluorescence
    Furrer D; Jacob S; Caron C; Sanschagrin F; Provencher L; Diorio C
    Anticancer Res; 2017 Jun; 37(6):3323-3329. PubMed ID: 28551685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas.
    Mentrikoski MJ; Stoler MH
    Am J Surg Pathol; 2014 Jun; 38(6):844-51. PubMed ID: 24698965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of HER2 by automated FISH and IHC in gastric carcinoma biopsies.
    Silva MR; Alarcão A; Ferreira T; d'Aguiar M; Ladeirinha A; Balseiro S; Carvalho L
    Int J Biol Markers; 2016 Feb; 31(1):e38-43. PubMed ID: 26349667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A meta-analysis on concordance between immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) to detect HER2 gene overexpression in breast cancer.
    Bahreini F; Soltanian AR; Mehdipour P
    Breast Cancer; 2015 Nov; 22(6):615-25. PubMed ID: 24718809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 immunohistochemistry in endometrial and ovarian clear cell carcinoma: discordance between antibodies and with in-situ hybridisation.
    Koopman T; van der Vegt B; Dijkstra M; Bart J; Duiker E; Wisman GBA; de Bock GH; Hollema H
    Histopathology; 2018 Nov; 73(5):852-863. PubMed ID: 29989198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.